Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,338 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05952947RecruitingPhase 1
Study drug for HPV18-positive solid tumors with a specific immune marker
This Phase 1 trial tests HRYZ-T101 injection for people whose solid cancer is HPV18-positive and who have the HLA-DRB1*0901 immune marker. It is meant for people whose cancer has returned or spread and who have few or no effective treatment options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05759546RecruitingPhase 2
Test a PARP and CDK4/6 medicine plus hormone therapy
This Phase 2 study tests whether combining a PARP inhibitor with a CDK4/6 inhibitor and hormone (endocrine) therapy can help people with advanced HR-positive, HER2-negative breast cancer. It’s for certain patients who have not yet had chemotherapy or targeted therapy for metastatic disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05912075RecruitingPhase 1
New pre-surgery radiation plus ASTX660 for rectal cancer
This early-phase trial tests adding ASTX660 (a new drug) to pre-surgery radiation for locally advanced rectal cancer. It aims to improve control of the tumor before surgery, making it more likely that the surgeon can remove it with clear margins.
Lyon, RhöneAges 18 years+ - NCT07173387RecruitingPhase 2
Radiation plus chemo for locally advanced pancreatic cancer
This trial combines focused radiation with a chemotherapy drug combo to help shrink or control locally advanced pancreatic cancer. If it works, this treatment might make the tumor smaller and improve quality of life.
Jinan, ShandongAges 18–75 - NCT06251388RecruitingPhase 2
Chemoradiation plus Cadonilimab for advanced cervical cancer
This trial tests whether adding an immunotherapy drug called Cadonilimab (AK104) to standard chemoradiation can help people with locally advanced cervical cancer that has not spread to distant organs. The goal is to improve treatment outcomes for those who cannot have surgery.
Chengdu, SichuanAges 18–75 - NCT06254521RecruitingPhase 2
Tislelizumab plus chemo before surgery for MSS rectal cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) plus chemotherapy before surgery for people with a specific type of rectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor more effectively than standard treatment.
Nanning, GuangxiAges 18 years+ - NCT06044311RecruitingPhase 2
Vactosertib with chemo and radiation for esophageal cancer
This trial tests whether adding a new drug called vactosertib to standard chemotherapy and radiation before surgery can help treat esophageal adenocarcinoma. It aims to see if the combination is safe and effective for patients with stage II or III disease.
Cleveland, OhioAges 18 years+ - NCT06278870RecruitingPhase 3
New drug combo vs standard for HER2+ advanced breast cancer
This trial compares two drug combinations for HER2-positive breast cancer that has spread. It tests a newer drug (Disitamab Vedotin + Pyrotinib) against a standard treatment (THP) as a first treatment option.
Guangzhou, GuangdongAges 18–75 - NCT07858630Recruiting
Radiation targeting for advanced esophageal cancer with immunotherapy
This trial studies how to best target radiation for people with advanced esophageal cancer who are also getting immunotherapy. It aims to improve treatment planning to help patients live longer with fewer side effects.
Beijing, Beijing MunicipalityAges 18–80 - NCT06187597RecruitingPhase 2
Toripalimab after chemoradiation for older esophageal cancer
This study tests whether adding a drug called toripalimab after standard chemoradiation can help older adults with esophageal cancer. The goal is to see if this treatment can keep the cancer from coming back after initial therapy.
Guangzhou, GuangdongAges 70–85 - NCT06202261RecruitingPhase 1/Phase 2
Study of TQB2930 for breast cancer that has returned or spread
This trial tests a new drug called TQB2930 alone or with other treatments for people with recurrent or metastatic breast cancer. It may help if you have a type of breast cancer called HER2-positive and have not had many prior treatments for advanced disease.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06306846RecruitingPhase 2
Radiation and immunotherapy before surgery for head and neck cancer
This study tests giving a short course of targeted radiation (SBRT) along with immunotherapy and a targeted drug before surgery for advanced head and neck cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
Hangzhou, ZhejiangAges 18–70 - NCT06304350RecruitingPhase 2
Pembrolizumab plus chemo before surgery for esophageal cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (given before surgery) can help shrink stage II/III esophageal cancer. The goal is to make surgery more likely to remove all cancer and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05798793RecruitingPhase 3
Chemo plus anti–PD-1 before surgery for mouth cancer
This trial studies whether giving anti–PD-1 immunotherapy together with chemotherapy before surgery can improve outcomes for people with locally advanced, operable oral squamous cell carcinoma. It aims to shrink the cancer and make surgery more effective by treating both the tumor and the immune response.
Shenzhen, GuangdongAges 18–70 - NCT05186493Recruiting
Robot-assisted surgery for advanced pelvic cancer
This study looks at a robot-assisted, minimally invasive surgery approach for people with advanced pelvic cancer that needs a pelvic exenteration operation. It may help some patients have surgery with smaller cuts, depending on whether they are good candidates for this type of procedure.
OsloAges 18 years+ - NCT06354218RecruitingPhase 2
Serplulimab plus chemoradiation for older adults with esophageal cancer
This trial tests a new immunotherapy drug called serplulimab combined with standard chemotherapy and radiation for older adults with locally advanced esophageal cancer. It aims to see if this combination can help shrink tumors and improve outcomes without prior cancer treatment.
Nanjing, JiangsuAges 75 years+ - NCT06354530RecruitingPhase 2/Phase 3
Study of pre-surgery therapy for advanced esophageal cancer
This trial tests a combination of drugs (anlotinib, immunotherapy, and chemotherapy) given before surgery for esophageal cancer that has not spread to other organs. The goal is to see if this approach shrinks the tumor and improves outcomes.
Chongqing, None SelectedAges 18–80 - NCT05905315RecruitingPhase 2
Vulvar cancer treatment: chemoradiation vs chemotherapy then surgery
This Phase 2 trial compares two treatment approaches for some women with vulvar squamous cell cancer: chemoradiation first, or chemotherapy first followed by surgery. The goal is to see which strategy works better or is safer for tumors that are hard to remove without major pelvic surgery.
AmsterdamAges 18 years+ - NCT06361784Recruiting
Heart-Sparing Radiation for Stage 3 Lung Cancer
This study tests a new way of planning radiation therapy for stage 3 lung cancer. By carefully mapping the heart's structure, doctors aim to protect it from radiation and improve treatment safety.
MilanAges Any age - NCT06387056RecruitingPhase 2
Gene-guided hormone therapy before prostate cancer surgery
This trial tests whether giving a combination of hormone treatments before surgery can improve outcomes for men with prostate cancer that has spread locally or to a few bone spots. It uses genetic testing to match participants with the most effective treatment.
Xiamen, FujianAges 18 years+ - NCT04680377Recruiting
Using gut microbes to predict durvalumab side effects in lung cancer
This study looks at the microbiome (the tiny organisms in your gut) to try to predict who will get side effects from durvalumab after chemoradiation. If you join, your care team will use your microbiome results to help understand toxicity risk and improve future treatment planning.
Kansas City, KansasAges 18 years+ - NCT06421298RecruitingPhase 2
Tafolecimab and sintilimab plus chemo for advanced lung cancer
This trial is testing a new combination of treatments, including an immune drug (sintilimab) and a cholesterol-lowering drug (tafolecimab), along with chemotherapy, for people with advanced lung cancer that no longer responds to standard immunotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT07850882Recruiting
Virus injection plus immunotherapy for advanced colorectal, stomach, or liver cancer
This study tests whether a special virus injected directly into tumors can help your body fight cancer when combined with an immunotherapy drug. It is for people with advanced colorectal, stomach, or liver cancer that has spread and who have tumors that can be reached for injection.
Guangdong, FoshanAges 18–75 - NCT06427460RecruitingPhase 2
Focused radiation therapy for solid tumors
This trial tests a special type of radiation that delivers a higher dose to the center of the tumor while limiting radiation to nearby healthy organs. It's for people with certain solid tumors that haven't spread widely or have only a few metastases.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,338 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.